Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations w...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group
Format:	Artigo
Jezik:	Inglês
Izdano:	Oxford University Press 2025-04-01
Serija:	ESC Heart Failure
Teme:	vericiguat soluble guanylate cyclase stimulators heart failure clinical trial
Online dostop:	https://doi.org/10.1002/ehf2.15134
Oznake:	Označite Brez oznak, prvi označite!